Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
49.42
+0.88 (+1.82%)
Streaming Delayed Price
Updated: 9:51 AM EDT, Jun 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
22
23
Next >
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
↗
August 07, 2024
EXEL earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
EXEL stock results show that Exelixis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
↗
May 01, 2024
Via
Benzinga
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
↗
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via
Chartmill
What Analysts Are Saying About Exelixis Stock
↗
April 10, 2024
Via
Benzinga
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
↗
August 06, 2024
U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy...
Via
Benzinga
Topics
Economy
Stocks
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Exelixis, Inc.
Via
Business Wire
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
↗
August 06, 2024
Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend.
Via
Benzinga
Topics
Stocks
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
↗
July 18, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
7 Cheap Biotech Stocks With Major Upside Potential
↗
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
↗
June 27, 2024
When you look at EXELIXIS INC (NASDAQ:EXEL), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
↗
June 06, 2024
EXELIXIS INC (NASDAQ:EXEL) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
↗
May 31, 2024
Via
Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
↗
May 31, 2024
Via
Benzinga
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 28, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 20, 2024
From
Exelixis, Inc.
Via
Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
↗
May 15, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
↗
May 12, 2024
These stocks are both experts in their respective fields.
Via
The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
↗
May 10, 2024
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Via
Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
↗
May 08, 2024
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.
Via
InvestorPlace
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
May 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
↗
May 01, 2024
EXEL earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
↗
April 30, 2024
EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 30, 2024
From
Exelixis, Inc.
Via
Business Wire
The Top 3 Biotech Stocks to Buy in April 2024
↗
April 27, 2024
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.
Via
InvestorPlace
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
April 16, 2024
From
Exelixis, Inc.
Via
Business Wire
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
↗
March 29, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
